Boundless Bio (BOLD) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Boundless Bio (BOLD) has outperformed Kazia Therapeutics (KZIA) over the past year, gaining 105.3% versus a loss of 41.1%. Kazia Therapeutics is the larger company by market cap ($56.2 million vs $54.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | KZIA |
|---|---|---|
| Share price | $2.32 | $4.92 |
| Market cap | $54.78M | $56.22M |
| 1-day change | -2.52% | -8.38% |
| YTD return | +93.33% | -28.59% |
| 1-year return | +105.31% | -41.08% |
| 5-year return | — | -99.01% |
| EPS (TTM) | $-2.46 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-58.20M | — |
| 52-week high | $3.16 | $17.40 |
| 52-week low | $0.961 | $4.50 |
| Distance from 52-week high | -26.68% | -71.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +72.41% | +476.02% |
| Average volume | 131.34K | 307.30K |
| Shares outstanding | 23.61M | 11.43M |
| Employees | 28 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed KZIA by 146.4 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
BOLD vs KZIA FAQ
Which is bigger, Boundless Bio or Kazia Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $56.22M compared with $54.78M for Boundless Bio (BOLD).
Which stock has performed better over the past year, BOLD or KZIA?
BOLD returned +105.31% over the past 12 months, compared with -41.08% for KZIA (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.